CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Biocure Technology Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Biocure Technology Inc
300-1055 West Hastings Street
Phone: (604) 609-7149p:604 609-7149 VANCOUVER, BC  V6E 2E9  Canada Ticker: CURE.XCURE.X
Business Summary
Biocure Technology Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of its own CAR T-cell therapy, targeting Chronic lymphocytic leukemia and solid tumor cancers. Additionally, the Company is developing biosimilar technologies for cancer treatment. The Company’s products include Interferon Beta, Ranibizumab and PEG-Filgrastim.
(Source: 10-K405)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023Yes----

Industries
SIC Code Description
1099 Miscellaneous metal ores, not elsewhere classified
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer, Director Yee SingCheng 9/13/2023 9/13/2023
Chief Financial Officer, Corporate Secretary, Director KonstatinLichtenwald 3/1/2018 3/1/2018
Director HansFrykman 9/4/2018 9/4/2018
Independent Director DannyJoh 3/13/2019 3/13/2019
Independent Director Sang GooKim 3/1/2018 8/28/2015

Business Names
Business Name
1WH
BiocurePharm, Korea
CURE
CURE.X
Sukari Ventures Corp.

General Information
Outstanding Shares: 10,444,504 (As of 10/28/2024)
Stock Exchange: CNQ
Fax Number: (604) 609-7149
Email Address: info@biocuretech.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024